Related Experiment Video
Updated: Aug 5, 2026
Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Twelve-month changes in lipid-derived cardiovascular risk indices among patients with psoriasis receiving biologic
Bahadır Aslancan1, Nur Ecer2, Ayşegül Tel Kankılıç3
1Department of Dermatology and Venereology, Şanlıurfa Training and Research Hospital, Şanlıurfa, Türkiye.
Background:
Biologic agents have transformed moderate-to-severe psoriasis treatment, but their real-world effect on lipid-derived cardiovascular risk markers remains unclear.
Research Design And Methods:
This multicenter retrospective cohort included 113 adults with moderate-to-severe plaque psoriasis treated with a biologic for 12 months in routine practice. Patients with chronic systemic disease or confounding concomitant medication were excluded; psoriatic arthritis was retained as a covariate. Six lipid-derived indices, including the atherogenic index of plasma (AIP), were calculated at baseline and month 12. The primary outcome was the 12-month change in AIP; drug- and class-level comparisons and multivariable regression were exploratory.
Results:
AIP was the only index that changed significantly, rising from 0.497 ± 0.339 to 0.563 ± 0.289 (mean change 0.066 ± 0.286; p = 0.016; bootstrap 95% CI 0.014 to 0.120); the other five indices remained stable. Baseline AIP, smoking, and psoriatic arthritis were independently associated with this change. Treatment subgroups were small and unbalanced, so drug- and class-level findings are hypothesis-generating.
Conclusions:
Lipid-derived indices changed selectively rather than uniformly. Given its modest magnitude and the absence of psoriasis-specific thresholds, the AIP increase is better read as a dynamic shift in the triglyceride/high-density lipoprotein cholesterol axis than as worsening cardiovascular risk.
